Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 78

Sort by

Sort Order Select

Journal Articles

Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients

Hira Mian, Mariano Arribas, Rafael Fonseca, Erin Mutterback, Omar Shahid, Rohan Gouda, Gregory Russell Pond, Alissa Visram

Blood Adv bloodadvances.2025018655.

https://doi.org/10.1182/bloodadvances.2025018655

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Heta Patel, Harper Hubbeling, Kyle L. Yu, Maribel Carpenter, Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, Shivani Kapur, Dan T Vogl, Adam J Waxman, Edward A Stadtmauer, Alfred L Garfall, Sandra Patricia Susanibar-Adaniya

Blood Adv bloodadvances.2025017939.

https://doi.org/10.1182/bloodadvances.2025017939

Published: 2025

Includes: Supplemental data

Journal Articles

Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing

Baijun Fang, Zunmin Zhu, Yinyin Chang, Xiangxiang He, Shiyong Li, Manqian Li, Susu Yan, Dandan Zhu, Zhenling Li, Mao Mao

Blood Adv bloodadvances.2025018133.

https://doi.org/10.1182/bloodadvances.2025018133

Published: 2025

Includes: Supplemental data

Journal Articles

Prognosis and patterns of progression in smoldering multiple myeloma

Theresia Akhlaghi, Kylee H. Maclachlan, Adriana Wiggins, Saad Z. Usmani, Andriy Derkach, Malin L Hultcrantz

Blood Adv bloodadvances.2025018021.

https://doi.org/10.1182/bloodadvances.2025018021

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world evidence of measurable residual disease assessment in multiple myeloma

Blood Adv bloodadvances.2025018454.

https://doi.org/10.1182/bloodadvances.2025018454

Published: 2025

Includes: Supplemental data

Journal Articles

Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going

Elena Zamagni, Marco Talarico

Blood Adv (2025) 9 (24): 6252–6266.

https://doi.org/10.1182/bloodadvances.2024015686

Published: 2025

Journal Articles

Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma

Maria Teresa Bilotta, Antonio Giovanni Solimando, Vanessa Desantis, Lucia Di Marzo, Andrea Sabatini, Sergio Forcelloni, Alessandro Andriano, Arcangelo Morizio, Antonella Argentiero, Roberto Ria, Linda Quatrini, Lorenzo Moretta, Paola Vacca, Nicola Tumino

Blood Adv (2025) 9 (24): 6246–6251.

https://doi.org/10.1182/bloodadvances.2025016659

Published: 2025

Includes: Supplemental data

Journal Articles

mTOR activity and metabolic reprogramming of CD8 + T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Taylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, Emma L. Bishop, Bryan Marzullo, Hannah Giles, Graham McIlroy, Paul Ferguson, Bhuvan Kishore, Kate Rogers, Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, Guy Pratt, Sarah Dimeloe

Blood Adv (2025) 9 (23): 6175–6188.

https://doi.org/10.1182/bloodadvances.2025016439

Published: 2025

Includes: Supplemental data

Journal Articles

Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma

Phyllis SY Chong, SL Julia Lim, Tuan Zea Tan, Li Ren Kong, Sanjay De Mel, Aaron Leow Chung Yong, Ernest Yap Gim Seng, Wee-Joo Chng

Blood Adv bloodadvances.2025017676.

https://doi.org/10.1182/bloodadvances.2025017676

Published: 2025

Includes: Supplemental data

Journal Articles

Ig Replacement After Bispecifics Requires Randomized Trial

Yung Gonzaga, Marcio Nucci, Elias Anaissie

Blood Adv bloodadvances.2025018013.

https://doi.org/10.1182/bloodadvances.2025018013

Published: 2025

Journal Articles

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia

Blood Adv (2025) 9 (23): 6009–6018.

https://doi.org/10.1182/bloodadvances.2025016966

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Blood Adv (2025) 9 (22): 5814–5827.

https://doi.org/10.1182/bloodadvances.2025017214

Published: 2025

Includes: Supplemental data

Journal Articles

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS

Jón Þórir Óskarsson, Sigrun Thorsteinsdottir, Sæmundur Rögnvaldsson, Andri Ólafsson, Gunnhildur Viðarsdóttir, Elfa Rún Guðmundsdóttir, Elias Eythorsson, Ásbjörn Jónsson, Brynjar Viðarsson, Páll T. Önundarson, Bjarni A. Agnarsson, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Stephen J. Harding, Brian GM Durie, Thorvardur Jon Love, Sigurdur Y. Kristinsson

Blood Adv (2025) 9 (21): 5455–5459.

https://doi.org/10.1182/bloodadvances.2025017270

Published: 2025

Journal Articles

Impact of body mass index on the prognosis of patients with newly diagnosed Multiple Myeloma

Kevin D Arnold, Krystle L Ong, Gayathri Ravi, Meredith C Wessel, Faith E. Davies, Luciano J. Costa, Ananya Deshpande, Gareth J. Morgan, Brenda M Birmann, Elizabeth E Brown

Blood Adv bloodadvances.2025018024.

https://doi.org/10.1182/bloodadvances.2025018024

Published: 2025

Includes: Supplemental data

Journal Articles

Molecular and immunological determinants of long-term survival in multiple myeloma

Khanmi Kasomva, Kritika Yadav, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood Adv (2025) 9 (20): 5134–5147.

https://doi.org/10.1182/bloodadvances.2025016829

Published: 2025

Journal Articles

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

Parvathi Sudha, Phillip Pham, Wen Niu, Enze Liu, Lin Wang, Gillian Truong, Cameron Ligocki, Ramzi Al-Azzawi, Mallini Surapenini, Steven Bray, Francesco Vetrini, Magdalena Czader, Marwan Tayeh, Kelvin P Lee, Rafat Abonour, Attaya Suvannasankha, Brian A Walker

Blood Adv bloodadvances.2025017721.

https://doi.org/10.1182/bloodadvances.2025017721

Published: 2025

Includes: Supplemental data

Journal Articles

AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

Blood Adv bloodadvances.2025017488.

https://doi.org/10.1182/bloodadvances.2025017488

Published: 2025

Includes: Supplemental data

Journal Articles

Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model

Michael Riley Dyer, Alexander Zheleznyak, Erin N. Teubner, Julie Prior, Brad Manion, Zhenghan Jing, Amit K. Sharma, Junwei Du, Rui Tang, Mark A Fiala, John F. DiPersio, Deborah Veis, Julie O'Neal, Mikhail Y. Berezin, Monica Shokeen

Blood Adv bloodadvances.2025017296.

https://doi.org/10.1182/bloodadvances.2025017296

Published: 2025

Journal Articles

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Andrew Kowalski, Jill Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James Hoffman, Abhishek Pandey, Dickran Kazandjian, Ola Landgren

Blood Adv (2025) 9 (19): 4979–4986.

https://doi.org/10.1182/bloodadvances.2025016911

Published: 2025

Journal Articles

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Michael Sang Hughes, Samuel Pan, Rajshekhar Chakraborty, Jayant Raikhelkar, Mathew S. Maurer, Markus Y. Mapara, Andrew Eisenberger, Suzanne Lentzsch, Divaya Bhutani

Blood Adv (2025) 9 (19): 4946–4950.

https://doi.org/10.1182/bloodadvances.2025016731

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Real world comparison of progression free survival and time to next therapy in 761 newly diagnosed multiple myeloma patients

Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing

Prognosis and patterns of progression in smoldering multiple myeloma

Real-world evidence of measurable residual disease assessment in multiple myeloma

Fifteen years of use of functional imaging in multiple myeloma: where we started and where we are going

Progressive NK-cell dysfunction and ILC imbalance favor immune evasion in multiple myeloma

mTOR activity and metabolic reprogramming of CD8 + T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Bioenergetic diversity and nutrient auxotrophy shape the metabolic landscape of Multiple Myeloma

Ig Replacement After Bispecifics Requires Randomized Trial

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Next-generation flow cytometry analysis of clonal bone marrow plasma cells identifies an indolent subset of MGUS

Impact of body mass index on the prognosis of patients with newly diagnosed Multiple Myeloma

Molecular and immunological determinants of long-term survival in multiple myeloma

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

AL Amyloidosis: A Real-World Experience with CAR-T Cell Therapy

Ablation of CD38 in Multiple Myeloma Cells Leads to an Aggressive Phenotype in a Mouse Xenograft Model

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only